NCT00941330 - Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Breast Cancer

Interventions

DRUG

Exemestane

25 mg daily by mouth for 6 to 12 months.

DRUG

Docetaxel

Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).

DRUG

Cytoxan

Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).

Trial Locations (3)

Grady Memorial Hospital, Atlanta

Emory University Hospital Midtown, Atlanta

Emory University Winship Cancer Institute, Atlanta